Your browser is no longer supported. Please, upgrade your browser.
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-2.83 Insider Own0.40% Shs Outstand121.22M Perf Week7.48%
Market Cap462.78M Forward P/E- EPS next Y-1.44 Insider Trans-6.38% Shs Float116.49M Perf Month-27.52%
Income-299.10M PEG- EPS next Q-0.40 Inst Own48.50% Short Float22.72% Perf Quarter-28.18%
Sales156.10M P/S2.96 EPS this Y41.10% Inst Trans9.77% Short Ratio8.21 Perf Half Y-47.07%
Book/sh-1.86 P/B- EPS next Y39.60% ROA-53.50% Target Price5.94 Perf Year-38.16%
Cash/sh- P/C- EPS next 5Y- ROE147.30% 52W Range2.70 - 11.10 Perf YTD-34.17%
Dividend- P/FCF- EPS past 5Y14.90% ROI-75.30% 52W High-71.53% Beta1.66
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin74.40% 52W Low16.82% ATR0.24
Employees429 Current Ratio2.00 Sales Q/Q-2.30% Oper. Margin- RSI (14)40.77 Volatility8.42% 6.80%
OptionableYes Debt/Eq- EPS Q/Q37.60% Profit Margin- Rel Volume0.97 Prev Close3.08
ShortableYes LT Debt/Eq- EarningsNov 03 BMO Payout- Avg Volume3.22M Price3.16
Recom3.30 SMA20-7.59% SMA50-21.23% SMA200-38.33% Volume3,141,524 Change2.60%
May-18-20Reiterated H.C. Wainwright Buy $29 → $33
Apr-27-20Downgrade SVB Leerink Mkt Perform → Underperform $5
Apr-09-20Downgrade BofA/Merrill Neutral → Underperform $6
Jan-08-20Reiterated H.C. Wainwright Buy $36 → $27
Nov-19-19Downgrade Evercore ISI Outperform → In-line $8
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
Dec-03-21 11:31AM  
Nov-04-21 06:46AM  
Nov-03-21 09:15AM  
Oct-27-21 03:03PM  
Oct-20-21 08:00AM  
Oct-19-21 08:00AM  
Oct-15-21 09:15AM  
Oct-07-21 09:00AM  
Sep-29-21 10:00AM  
Sep-20-21 08:00AM  
Sep-03-21 11:31AM  
Aug-27-21 11:37AM  
Aug-24-21 02:00AM  
Aug-16-21 04:21PM  
Aug-05-21 10:57AM  
Aug-04-21 09:15AM  
Jul-28-21 03:03PM  
Jul-21-21 08:00AM  
Jul-12-21 04:05PM  
Jun-28-21 07:00AM  
Jun-23-21 07:00AM  
Jun-15-21 05:39AM  
Jun-12-21 06:49AM  
Jun-10-21 04:30PM  
Jun-09-21 11:00AM  
Jun-04-21 11:31AM  
May-19-21 06:27PM  
May-17-21 04:15PM  
May-07-21 03:09AM  
May-06-21 10:39AM  
May-05-21 10:04AM  
Apr-28-21 04:05PM  
Apr-21-21 04:00PM  
Apr-10-21 08:30AM  
Mar-25-21 11:30AM  
Mar-22-21 09:50AM  
Mar-19-21 04:30PM  
Mar-02-21 10:21AM  
Feb-23-21 09:24AM  
Feb-22-21 10:14AM  
Feb-17-21 08:00AM  
Feb-11-21 08:00AM  
Feb-06-21 02:41AM  
Feb-04-21 08:00AM  
Feb-02-21 10:00AM  
Jan-11-21 08:00AM  
Dec-30-20 06:49AM  
Dec-29-20 08:00AM  
Dec-22-20 10:28AM  
Dec-21-20 10:05AM  
Dec-16-20 10:51PM  
Dec-10-20 08:55AM  
Dec-05-20 11:32AM  
Nov-24-20 06:06PM  
Nov-20-20 08:00AM  
Nov-08-20 07:40AM  
Nov-06-20 10:43AM  
Nov-05-20 09:25AM  
Oct-29-20 12:35PM  
Oct-20-20 04:05PM  
Oct-14-20 10:15PM  
Oct-13-20 06:47AM  
Sep-17-20 03:05AM  
Sep-10-20 08:05AM  
Sep-09-20 08:05AM  
Sep-08-20 04:19PM  
Sep-05-20 11:31AM  
Aug-27-20 09:58AM  
Aug-26-20 07:23PM  
Aug-18-20 10:36AM  
Aug-17-20 03:13PM  
Aug-07-20 11:44AM  
Aug-06-20 07:10PM  
Aug-05-20 08:05AM  
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. It also provides lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company distributes its products primarily through specialty pharmacies and distributors to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, and Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IVERS-READ GILLIAN CSee RemarksDec 02Sale3.00304912260,041Dec 03 04:15 PM
Harding Thomas C.See RemarksDec 02Sale3.007211,542Dec 03 04:15 PM
Harding Thomas C.See RemarksDec 02Sale3.001414235,395Dec 03 04:15 PM
MUEHL DANIEL WSee RemarksDec 02Sale3.0024874467,403Dec 03 04:16 PM
Rolfe LindseySee RemarksDec 02Sale3.003461,03882,628Dec 03 04:16 PM
Gross Paul EdwardSee RemarksDec 02Sale3.0024874461,357Dec 03 04:15 PM
Rolfe LindseySee RemarksNov 02Sale4.554,20919,15179,987Nov 03 04:18 PM
IVERS-READ GILLIAN CSee RemarksNov 02Sale4.553,69616,817257,074Nov 03 04:19 PM
Harding Thomas C.See RemarksNov 02Sale4.55622821,531Nov 03 04:15 PM
Harding Thomas C.See RemarksNov 02Sale4.551,6827,6534,346Nov 03 04:15 PM
MUEHL DANIEL WSee RemarksNov 02Sale4.554,52320,58064,505Nov 03 04:15 PM
Gross Paul EdwardSee RemarksNov 02Sale4.554,52320,58058,459Nov 03 04:15 PM
Harding Thomas C.See RemarksOct 04Sale4.416261,412Oct 05 04:31 PM
Harding Thomas C.See RemarksSep 02Sale4.897341,403Sep 03 05:21 PM
Harding Thomas C.See RemarksSep 02Sale4.891416893,563Sep 03 05:21 PM
IVERS-READ GILLIAN CSee RemarksSep 02Sale4.893041,487254,980Sep 03 04:15 PM
Rolfe LindseySee RemarksSep 02Sale4.893471,69778,122Sep 03 04:15 PM
Gross Paul EdwardSee RemarksSep 02Sale4.892491,21855,318Sep 03 04:15 PM
MUEHL DANIEL WSee RemarksSep 02Sale4.892491,21861,364Sep 03 04:16 PM
IVERS-READ GILLIAN CSee RemarksAug 03Sale4.823,68317,752252,005Aug 03 09:40 PM
Harding Thomas C.See RemarksAug 03Sale4.82622991,391Aug 03 09:38 PM
Harding Thomas C.See RemarksAug 03Sale4.821,6788,0882,511Aug 03 09:38 PM
MUEHL DANIEL WSee RemarksAug 03Sale4.824,50721,72458,459Aug 03 09:36 PM
Rolfe LindseySee RemarksAug 03Sale4.824,19520,22075,473Aug 03 09:32 PM
Gross Paul EdwardSee RemarksAug 03Sale4.824,50721,72452,413Aug 03 09:31 PM
Harding Thomas C.See RemarksJul 01Sale5.79261511,272Jul 06 04:16 PM
Gross Paul EdwardSee RemarksJun 03Sale5.632311,30149,262Jun 03 07:03 PM
MUEHL DANIEL WSee RemarksJun 03Sale5.632311,30155,308Jun 03 07:01 PM
Rolfe LindseySee RemarksJun 03Sale5.633221,81373,602Jun 03 07:00 PM
IVERS-READ GILLIAN CSee RemarksJun 03Sale5.632831,593249,905Jun 03 06:58 PM
Harding Thomas C.See RemarksJun 03Sale5.637391,235Jun 03 06:57 PM
Harding Thomas C.See RemarksJun 03Sale5.631317381,725Jun 03 06:57 PM
IVERS-READ GILLIAN CSee RemarksMay 04Sale5.543,95221,894247,059May 04 09:43 PM
MUEHL DANIEL WSee RemarksMay 04Sale5.544,83726,79752,008May 04 09:40 PM
Rolfe LindseySee RemarksMay 04Sale5.544,50124,93671,098May 04 09:39 PM
Harding Thomas C.See RemarksMay 04Sale5.54804431,224May 04 09:40 PM
Harding Thomas C.See RemarksMay 04Sale5.541,7999,966729May 04 09:40 PM
Gross Paul EdwardSee RemarksMay 04Sale5.544,83826,80344,870May 04 09:39 PM
Harding Thomas C.See RemarksMar 12Sale6.001,98711,9221,123Mar 15 04:15 PM
Harding Thomas C.See RemarksMar 12Sale5.997,36744,1280Mar 15 04:15 PM
IVERS-READ GILLIAN CSee RemarksMar 02Sale6.295803,648244,695Mar 03 06:42 PM
Harding Thomas C.See RemarksMar 02Sale6.298503,110Mar 03 06:41 PM
Harding Thomas C.See RemarksMar 02Sale6.292991,8817,241Mar 03 06:41 PM
Gross Paul EdwardSee RemarksMar 02Sale6.294562,86843,207Mar 03 06:40 PM
Rolfe LindseySee RemarksMar 02Sale6.296614,15869,022Mar 03 06:35 PM
MUEHL DANIEL WSee RemarksMar 01Sale6.294562,86847,252Mar 03 06:46 PM
IVERS-READ GILLIAN CSee RemarksFeb 02Sale7.9710,99087,590234,877Feb 03 04:15 PM
Rolfe LindseySee RemarksFeb 02Sale7.9711,81394,15060,034Feb 03 04:15 PM
MUEHL DANIEL WSee RemarksFeb 02Sale7.9711,87294,62036,374Feb 03 04:15 PM
Harding Thomas C.See RemarksFeb 02Sale7.975,24841,8274,193Feb 03 04:15 PM
Gross Paul EdwardSee RemarksFeb 02Sale7.9711,87394,62832,063Feb 03 04:15 PM
Harding Thomas C.See RemarksFeb 02Sale8.178526,9612,687Feb 19 04:17 PM
Rolfe LindseySee RemarksDec 21Sale5.681,7289,81558,275Dec 23 04:52 PM
IVERS-READ GILLIAN CSee RemarksDec 21Sale5.688294,709233,086Dec 23 04:51 PM
Rolfe LindseySee RemarksDec 15Option Exercise3.2817,24156,55070,718Dec 16 04:15 PM
IVERS-READ GILLIAN CSee RemarksDec 10Option Exercise3.2868,965226,205284,487Dec 14 04:20 PM